Date: 2014-03-27
Type of information: Commercialisation agreement
Compound: ella® (ulipristal acetate - UPA)
Company: HRA Pharma (France) Afaxys Pharmaceuticals (USA - SC)
Therapeutic area: Gynecology - Women\'s health
Type agreement: commercialisation
Action mechanism:
Disease: emergency contraception
Details: * On March 27, 2014, HRA Pharma and Afaxys Pharmaceuticals, a division of Afaxys, have announced that the companies have formed a commercial partnership to supply ulipristal acetate (UPA), a selective progesterone receptor modulator, to the U.S. market. The product is commonly known as ella® in the U.S. where it has been available since 2010.
ella® is a next-generation emergency contraceptive developed by HRA Pharma specifically for emergency contraceptive use. ella® was originally approved as an emergency contraceptive by the European Medicines Agency (EMA) in 2009 and subsequently by the Food and Drug Administration (FDA) in 2010.
Financial terms:
Latest news:
